NVE Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for NVE Corporation, a developer and seller of spintronic devices (nanotechnology relying on electron spin). The report covers the quarterly and nine-month periods ended December 31, 2010. The company is an accelerated filer incorporated in Minnesota.
Key Financial Metrics
| Metric | Quarter Ended Dec 31, 2010 | Nine Months Ended Dec 31, 2010 |
|---|---|---|
| Total Revenue | $7,963,508 | $23,013,962 |
| Net Income | $3,383,919 | $9,691,026 |
| Diluted EPS | $0.70 | $2.00 |
| Gross Margin | 69.1% | 69.0% |
| Operating Cash Flow (9mo) | $8,952,319 | |
| Cash & Marketable Securities | $58,310,820 (as of Dec 31, 2010) | |
| Total Debt | None reported |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20.2% for the quarter and 15.3% for the nine-month period compared to the prior year. This was driven by a 26.3% (quarter) and 20.5% (nine-month) increase in product sales due to new customers and higher volume from existing customers.
- Contract Revenue Decline: Contract research and development revenue decreased 4.2% for the quarter and 6.1% for the nine-month period due to the completion of specific contracts.
- Expense Increases: Total expenses rose 21.0% for the quarter and 10.2% for the nine-month period. Research and development expenses increased significantly (31.4% for the quarter) due to increased product development activities.
- Interest Income: Interest income increased 23.5% for the quarter and 26.1% for the nine-month period, attributed to a larger portfolio of interest-bearing marketable securities.
- Inventory Build-up: Inventories increased by $1,457,731 over the nine-month period to support increased sales rates and raw material timing.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes working capital is adequate for the next 12 months. The company holds approximately 85% of its total assets in cash and marketable securities ($57.1 million in securities).
- Seasonality: The company noted that the typical seasonal weakness in quarters ending December 31 did not occur in fiscal 2010 or 2011, though future patterns are unpredictable.
- Key Risks:
- Customer Concentration: Significant revenue relies on agreements with large customers (St. Jude Medical, Avago Technologies, Phonak AG). Failure to renew these agreements could materially impact revenue.
- Investment Risk: The company holds a large portfolio of marketable securities. While currently rated highly, downgrades or defaults (citing the BP Capital Markets plc example) could result in losses.
- Stock Repurchase: No shares were repurchased under the $2.5 million authorization during the quarter.
Investor Verification Checklist
- Verify the renewal status and terms of supply agreements with major customers: St. Jude Medical (expires Dec 2011), Avago Technologies (expires June 2013), and Phonak AG (expires March 2015).
- Monitor the credit ratings of the $57.1 million marketable securities portfolio, particularly corporate bonds, for potential downgrades or impairment risks.
- Assess the sustainability of the 26% increase in product sales and whether it is driven by recurring demand or one-time orders.
- Review the trajectory of Research and Development expenses, which increased significantly, to ensure alignment with future product launches.